Folashade Otegbeye

[Folashade Otegbeye @DrShadeO]

My first bench to bedside experience! #NKcells @DrShadeO @paolocaimiMD @DrMarcosdelima @NK_papers

[ASTCT @ASTCT]

The administration of allogeneic natural killer (NK) cells following a lymphodepleting chemotherapy regimen is emerging as a well-tolerated therapeutic approach in the management of various malignancies. Read more of @DrShadeO article now: https://t.co/TfolLDDLh1

[Folashade Otegbeye @DrShadeO]

@drjgauthier This is what I worry about!

[Science in Seattle @science_seattle]

A new $5.2 million grant from WRF will help develop a new clinical trials program between @fredhutch & @seattlechildren.

The program, led by Dr. Folashade Otegbeye, will focus on first-in-human clinical studies of new therapeutics for rare cancers: https://t.co/UHv7HrktJn

[Fred Hutch Cancer Center @fredhutch]

A new $5.2M grant from the Washington Research Foundation will help launch a joint clinical trials program between Fred Hutch and @seattlechildren's, advancing first-in-human studies for rare cancers and other diseases that affect adults and children. https://t.co/d5Iyokuqbg

[Jordan Gauthier @drjgauthier]

⚠️Question for my CAR-T-treating colleagues⚠️
Which would you consider the most acceptable standard of care option for grade 2+ ICANS persistent or worsening after treatment with frontline dexamethasone?
Please repost 🙏
#equipoise #clinicaltrial #CARTcelltherapy

[Fred Hutch Cancer Center @fredhutch]

People with darker skin have more melanin, which can act like a “natural sunscreen,” but if you have darker skin, you can still get skin cancer, sometimes in places that receive very little sun.
#skincancer #sunscreen #skincare

[Folashade Otegbeye @DrShadeO]

@DrMarcosdelima Thanks @DrMarcosdelima! 😊

[Binaytara @binaytara]

Access to cellular therapy remains a challenge for many communities. Dr. Folashade Otegbeye's talk and the panel discussion with Dr. Mohamed Sorror, Dr. Melinda Biernacki, PA Lisa Getzendaner, and session chair @mshadman at #SCHD25 highlighted barriers and potential solutions. This conversation needs to continue beyond conference walls. #HealthEquity @fredhutch @UWMedicine

[ASTCT @ASTCT]

Congratulations to @sghmd, the 2025 recipient of the Lukas D. Wartman GVHD Achievement Award. #Tandem25

[ASTCT @ASTCT]

Session chair Jennifer Adair of @fredhutch kicks off today’s opening plenary on gene therapy at #Tandem25.

[Fred Hutch Cancer Center @fredhutch]

Meet the next generation of hematology and oncology leaders! The Fred Hutch/UW Hematology-Oncology Fellows are at #Tandem25 presenting their latest findings in transplantation, cell therapies, immunology and more. @emilyliangmd @HannahRAbrams

[Folashade Otegbeye @DrShadeO]

@fredhutch @SandmaierBrenda

[Folashade Otegbeye @DrShadeO]

Congratulations @masumi_ueda on a spectacular #Tandem25. In addition to her clinical trial report in the best abstracts plenary, she mentored medical students on two LTFU post-transplant clonal evolution studies also featured at the meeting. #NextGen mentor

[Fred Hutch Cancer Center @fredhutch]

Fred Hutch at #Tandem25: @masumi_ueda to present results of a novel drug regimen that shows great promise in preventing #cGVHD after transplant in people who received nonmyeloablative or reduced-intensity conditioning to treat a blood cancer. https://t.co/oq1KoAjaRY

[Folashade Otegbeye @DrShadeO]

Congratulations to two phenomenal clinicians who have excelled at leadership, mentorship and advocacy in the transplant and cell therapy field globally.
@DrMarcosdelima your inspired and selfless service remains instructive for me, your lifelong mentee. 💐

[ASTCT @ASTCT]

Congratulations to ASTCT Public Service Award recipients Mary E. Flowers, MD, of @fredhutch and Marcos de Lima, MD, of @OhioState. #Tandem25

[ASTCT @ASTCT]

Congratulations to ASTCT Public Service Award recipients Mary E. Flowers, MD, of @fredhutch and Marcos de Lima, MD, of @OhioState. #Tandem25

[ASTCT @ASTCT]

Upcoming best abstract presentation at #Tandem25: Masumi Ueda Oshima, MD, will present the results of a phase II study on a combination of PTCy, cyclosporine, and sirolimus for patients with GVHD.

Learn more: https://t.co/pDS2hf6zH5

[Folashade Otegbeye @DrShadeO]

Congratulations @ekimblepl on the @ASTCT New Investigator Award! Excited to see new approaches to CAR T cell therapy in AML. @fredhutch

[Fred Hutch Cancer Center @fredhutch]

Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger" for cGVHD, says Fred Hutch's @masumi_ueda. She will present the results, including updated data with longer follow-up of patients, on Feb. 14 at #Tandem25. https://t.co/79j0DD6cV7

[Fred Hutch Cancer Center @fredhutch]

Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger" for cGVHD, says Fred Hutch's @masumi_ueda. She will present the results, including updated data with longer follow-up of patients, on Feb. 14 at #Tandem25. https://t.co/79j0DD6cV7

[Fred Hutch Cancer Center @fredhutch]

"The fact that there wasn’t a major difference can offer some comfort to physicians and patients by showing that [allogeneic] transplantation does not result in higher acquisition of mutations," said @masumi_ueda.
https://t.co/Tm5fLRKIhk

[Fred Hutch Cancer Center @fredhutch]

Applications for the 7th Annual Dr. Eddie Méndez Award is now open! This award recognizes outstanding and diverse #postdocs who are conducting
#cancer, #infectiousdisease or #basicscience research. Apply by February 2, 2025 👉 https://t.co/SDmkIESwjb

#MendezSymposium